[시장보고서]색전요법 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

색전요법 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Embolotherapy Market Size, Share & Trends Analysis Report By Product, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869678

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 300 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

색전요법 시장 요약

세계의 색전요법 시장 규모는 2024년에 31억 6,000만 달러로 평가되었고, 2033년까지 58억 2,000만 달러에 이를 것으로 예측됩니다.

2025-2033년에 걸친 CAGR은 6.99%를 나타낼 전망입니다. 이 시장의 주요 성장 촉진요인은 암, 혈관 질환, 외상 사례 증가이며, 이들이 저침습 치료법 수요를 촉진하고 있습니다.

약물 용출성 비드, 액체 색전제, 생체 흡수성 마이크로스피어와 같은 색전제의 기술적 진보뿐만 아니라 마이크로카테터 및 플로우 다이버터와 같은 혁신적인 전달 장치로 치료의 정확성, 안전성 및 임상 결과를 향상시킵니다.

게다가 회복기간이 짧은 저침습 수술에 대한 환자의 선호가 높아지고, 신흥 시장에 있어서의 의료 인프라의 확충, 지원적인 규제 프레임워크이 더욱 보급을 가속화하고 있습니다. 이러한 요인이 함께 지속적인 성장 기회를 창출하고 시장의 상승 경향을 강화하고 있습니다.

세계적으로 암 치료, 외상 사례, 혈관 질환 증가를 볼 수 있기 때문에 고급 색전요법 솔루션의 필요성이 더욱 높아지고 있습니다. 병원, 클리닉, 인터벤셔널 라디오 로지 센터에서는 수기 건수가 증가하여 효과적인 색전제 및 전달 시스템에 대한 지속적인 수요가 발생하고 있습니다. 이 추세는 안전과 효율성을 유지하면서 환자 결과를 개선하는 혁신적이고 침습적인 기술의 도입을 의료시설에 더욱 강력하게 요구하고 있습니다. 이러한 요구에 부응하기 위해 의료 제공업체는 절차의 신속화, 정밀도 향상 및 합병증 감소를 가능하게 하는 차세대 색전요법 기술로의 전환을 가속화하고 있습니다.

예를 들어, 2025년 6월에는 Penumbra, Inc.가 미국 식품의약국(FDA)에 의한 승인을 취득하여 시장에서 최장, 최대, 최유연성을 자랑하는 Ruby XL System의 발매를 발표했습니다. Ruby XL System은 의사가 보다 효율적인 색전술을 시행할 수 있도록 설계되었으며, 특히 대혈관과 고유량 색전술을 동반한 치료에 있어서 방사선 피폭량의 저감과 치료 성과의 향상이 기대됩니다.

암과 혈관 질환의 유병률 상승은 색전요법 산업의 주요 성장 촉진요인입니다. 이러한 질환은 종종 출혈의 제어, 종양 크기의 감소 또는 비정상적인 혈관의 관리를 위해 표적화된 저침습 치료가 필요하기 때문입니다. 간암 환자는 종양으로의 혈액 공급을 차단하고 주위의 건강한 조직을 온존하면서 종양의 성장을 늦추기 때문에 경동맥적 색전술을 자주 받습니다. 동맥 정맥 기형과 소화관 출혈의 경우에도 개복 수술을 대체하는 효과적인 옵션으로 색전요법이 채용되는 경우가 증가하고 있습니다. 회복기간이 짧고 합병증도 적기 때문입니다. WHO의 추계에 의하면, 남녀를 불문하고(0-85세 이상)의 간암 및 간내 담관암의 신규 증례 수는 2022-2040년에 걸쳐 증가가 전망되고 있습니다. 자세한 내용은 데이터 프레임과 아래 그래프에 나와 있습니다.

지역별 전망
지역별 변동 분석과 시장 점유율(2024년 및 2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

시장 진출기업의 분류
주요 기업 프로파일
- Medtronic
- Johnson &Johnson
- B. Braun SE
- Terumo
- Boston Scientific Corporation
- Meril
- Gem srl
- Balt
- Sirtex(BlackSwan Vascular, Inc.)
- INVAMED
- Stryker
- Penumbra
- Merit Medical Systems
- Abbott
- Acandis GmbH
- Cook Medical

KTH

영문 목차

영문목차

Embolotherapy Market Summary

The global embolotherapy market size was estimated at USD 3.16 billion in 2024 and is projected to reach USD 5.82 billion by 2033, growing at a CAGR of 6.99% from 2025 to 2033. The market is primarily driven by the rising prevalence of cancer, vascular disorders, and trauma cases, which fuel demand for minimally invasive treatment options.

Technological advancements in embolic agents, such as drug-eluting beads, liquid embolic, and bioresorbable microspheres, along with innovative delivery devices like microcatheters and flow diverters, have improved procedural precision, safety, and clinical outcomes.

Moreover, increasing patient preference for less invasive procedures with shorter recovery times, expanding healthcare infrastructure in emerging markets, and supportive regulatory frameworks further accelerate adoption. Together, these factors create sustained growth opportunities and reinforce the market's upward trajectory.

The global rise in cancer treatments, trauma cases, and vascular disorders has amplified the need for advanced embolotherapy solutions. Hospitals, clinics, and interventional radiology centers are witnessing growing procedure volumes, creating continuous demand for effective embolic agents and delivery systems. This trend places additional pressure on healthcare facilities to adopt innovative, minimally invasive techniques that improve patient outcomes while maintaining safety and efficiency. To meet these needs, providers are increasingly turning to next-generation embolotherapy technologies that enable faster procedures, greater precision, and reduced complications.

For instance, in June 2025, Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared and launched the Ruby XL System, the longest, largest, and softest coil available on the market. The Ruby XL System is designed to enable physicians to perform more efficient embolizations, potentially decreasing radiation exposure and improving outcomes-particularly in procedures involving large vessels and high-flow embolizations.

The rising prevalence of cancer and vascular diseases is a major driver of the embolotherapy industry because these conditions often require targeted, minimally invasive treatments to control bleeding, reduce tumor size, or manage abnormal blood vessels. Patients with liver cancer frequently undergo transarterial embolization to block the blood supply to tumors, slowing their growth while preserving surrounding healthy tissue. Arteriovenous malformations or gastrointestinal bleeding cases are increasingly managed with embolotherapy, as it provides an effective alternative to open surgery with shorter recovery times and fewer complications. According to WHO, the estimated number of new cases of liver and intrahepatic bile duct cancers among both sexes (ages 0-85+) is projected to increase from 2022 to 2040, as shown in the data frame and illustrated in the graph below.

Global Embolotherapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global embolotherapy market report based on the product, application, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Embolization Coils
- Detachable Coils
- Pushable Coils
Embolic Agents
- Liquid Embolic Agents
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- N-BCA (n-Butyl Cyanoacrylate)
- N-HCA (n-Hexyl Cyanoacrylate)
- Cyanoacrylates
- Others
- Microspheres
Flow Diverters
Detachable Balloons
Vascular Plugs/Plug Systems
Support Devices
- Guidewires
- Microcatheters
Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
- Liver Cancer (Hepatocellular carcinoma)
- Renal Cell Carcinoma
- Lung Cancer
- Others
Peripheral Vascular Diseases
Neurovascular Abnormalities
Uterine Fibroid Embolization
Trauma and Bleeding Control
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals and Clinics
Ambulatory Surgical Centers
Other End-Use
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. Information Procurement
1.4. Purchased database.
1.5. GVR's internal database
1.6. Secondary sources
1.7. Third Party Perspective
1.8. Primary research
1.9. Details of primary research
- 1.9.1. Information or Data Analysis
- 1.9.2. Data analysis models
- 1.9.3. Market Formulation & Validation
- 1.9.4. Model Details
1.10. Commodity flow analysis (Model 1)
- 1.10.1. Approach 1: Commodity flow approach
1.11. Volume price analysis (Model 2)
- 1.11.1. Approach 2: Volume price analysis
1.12. List of Secondary Sources
1.13. List of Primary Sources
1.14. List of Abbreviations

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Embolotherapy Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Rising prevalence of cancer and vascular diseases
  - 3.2.1.2. Technological advancements in embolic agents and devices
  - 3.2.1.3. Increasing trauma and hemorrhage cases
  - 3.2.1.4. Growing preference for minimally invasive procedures
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Risk of complications
- 3.2.3. Market Opportunities Analysis
  - 3.2.3.1. Development of novel embolic agents
  - 3.2.3.2. Rising adoption of minimally invasive procedures
  - 3.2.3.3. Expansion into emerging markets
- 3.2.4. Market Challenges Analysis
  - 3.2.4.1. High cost of procedures and devices
3.3. Embolotherapy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining Power of Suppliers
  - 3.3.1.2. Bargaining Power of Buyers
  - 3.3.1.3. Threat of Substitutes
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political & Legal Landscape
  - 3.3.2.2. Economic and Social Landscape
  - 3.3.2.3. Technological Landscape

Chapter 4. Embolotherapy Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Embolotherapy Market: Product Movement Analysis & Market Share, 2024 & 2033
4.3. Embolization Coils
- 4.3.1. Embolization Coils Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.3.1.1. Detachable Coils
    - 4.3.1.1.1. Detachable Coils Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.3.1.2. Pushable Coils
    - 4.3.1.2.1. Pushable Coils Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Embolic Agents
- 4.4.1. Embolic Agents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.4.1.1. Liquid Embolic Agents
    - 4.4.1.1.1. Ethylene Vinyl Alcohol Copolymer (EVOH) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      - 4.4.1.1.1.1. N-BCA (n-Butyl Cyanoacrylate)
      - 4.4.1.1.1.2. N-HCA (n-Hexyl Cyanoacrylate)
    - 4.4.1.1.2. Cyanoacrylates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 4.4.1.1.3. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.4.1.2. Microspheres
    - 4.4.1.2.1. Microspheres Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Flow Diverters
  - 4.4.2.1. Flow Diverters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Detachable Balloons
  - 4.4.3.1. Detachable Balloons Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Vascular Plugs/Plug Systems
  - 4.4.4.1. Vascular Plugs/Plug Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.5. Support Devices
  - 4.4.5.1. Support Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 4.4.5.1.1. Guidewires
      - 4.4.5.1.1.1. Guidewires Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 4.4.5.1.2. Microcatheters
      - 4.4.5.1.2.1. Microcatheters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Embolotherapy Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Embolotherapy Market: Application Movement Analysis & Market Share, 2024 & 2033
5.3. Oncology
- 5.3.1. Oncology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Peripheral Vascular Diseases
- 5.4.1. Peripheral Vascular Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Neurovascular Abnormalities
- 5.5.1. Neurovascular Abnormalities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Uterine Fibroid Embolization
- 5.6.1. Uterine Fibroid Embolization Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Trauma and Bleeding Control
- 5.7.1. Trauma and Bleeding Control Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Embolotherapy Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Embolotherapy Market: End Use Movement Analysis & Market Share, 2024 & 2033
6.3. Hospitals and Clinics
- 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Ambulatory Surgical Centers
- 6.4.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Embolotherapy Market: Regional Estimates & Trend Analysis by Product, Application, End Use

7.1. Regional Outlook
7.2. Embolotherapy Market: Regional Movement Analysis & Market Share, 2024 & 2033
7.3. North America
- 7.3.1. North America Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Scenario
  - 7.3.2.4. Reimbursement Scenario
  - 7.3.2.5. U.S. Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Scenario
  - 7.3.3.4. Reimbursement Scenario
  - 7.3.3.5. Canada Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Scenario
  - 7.3.4.4. Reimbursement Scenario
  - 7.3.4.5. Mexico Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. Europe Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Scenario
  - 7.4.2.4. Reimbursement Scenario
  - 7.4.2.5. UK Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Scenario
  - 7.4.3.4. Reimbursement Scenario
  - 7.4.3.5. Germany Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Scenario
  - 7.4.4.4. Reimbursement Scenario
  - 7.4.4.5. France Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Competitive Scenario
  - 7.4.5.3. Regulatory Scenario
  - 7.4.5.4. Reimbursement Scenario
  - 7.4.5.5. Italy Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Competitive Scenario
  - 7.4.6.3. Regulatory Scenario
  - 7.4.6.4. Reimbursement Scenario
  - 7.4.6.5. Spain Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Competitive Scenario
  - 7.4.7.3. Regulatory Scenario
  - 7.4.7.4. Reimbursement Scenario
  - 7.4.7.5. Denmark Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
  - 7.4.8.1. Key Country Dynamics
  - 7.4.8.2. Competitive Scenario
  - 7.4.8.3. Regulatory Scenario
  - 7.4.8.4. Reimbursement Scenario
  - 7.4.8.5. Sweden Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key Country Dynamics
  - 7.4.9.2. Competitive Scenario
  - 7.4.9.3. Regulatory Scenario
  - 7.4.9.4. Reimbursement Scenario
  - 7.4.9.5. Norway Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Scenario
  - 7.5.2.4. Reimbursement Scenario
  - 7.5.2.5. Japan Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Scenario
  - 7.5.3.4. Reimbursement Scenario
  - 7.5.3.5. China Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Scenario
  - 7.5.4.4. Reimbursement Scenario
  - 7.5.4.5. India Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Scenario
  - 7.5.5.4. Reimbursement Scenario
  - 7.5.5.5. South Korea Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Australia
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Scenario
  - 7.5.6.4. Reimbursement Scenario
  - 7.5.6.5. Australia Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Thailand
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Scenario
  - 7.5.7.4. Reimbursement Scenario
  - 7.5.7.5. Thailand Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Latin America Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Scenario
  - 7.6.2.4. Reimbursement Scenario
  - 7.6.2.5. Brazil Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Scenario
  - 7.6.3.4. Reimbursement Scenario
  - 7.6.3.5. Argentina Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Middle East & Africa
- 7.7.1. Middle East & Africa Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Scenario
  - 7.7.2.4. Reimbursement Scenario
  - 7.7.2.5. South Africa Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Scenario
  - 7.7.3.4. Reimbursement Scenario
  - 7.7.3.5. Saudi Arabia Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Competitive Scenario
  - 7.7.4.3. Regulatory Scenario
  - 7.7.4.4. Reimbursement Scenario
  - 7.7.4.5. UAE Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key Country Dynamics
  - 7.7.5.2. Competitive Scenario
  - 7.7.5.3. Regulatory Scenario
  - 7.7.5.4. Reimbursement Scenario
  - 7.7.5.5. Kuwait Embolotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
8.2. Key Company Profiles
- 8.2.1. Medtronic
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Financial Performance
  - 8.2.1.3. Product Benchmarking
  - 8.2.1.4. Strategic Initiatives
- 8.2.2. Johnson & Johnson
  - 8.2.2.1. Company Overview
  - 8.2.2.2. Financial Performance
  - 8.2.2.3. Product Benchmarking
  - 8.2.2.4. Strategic Initiatives
- 8.2.3. B. Braun SE
  - 8.2.3.1. Company Overview
  - 8.2.3.2. Financial Performance
  - 8.2.3.3. Product Benchmarking
  - 8.2.3.4. Strategic Initiatives
- 8.2.4. Terumo
  - 8.2.4.1. Company Overview
  - 8.2.4.2. Financial Performance
  - 8.2.4.3. Product Benchmarking
  - 8.2.4.4. Strategic Initiatives
- 8.2.5. Boston Scientific Corporation
  - 8.2.5.1. Company Overview
  - 8.2.5.2. Financial Performance
  - 8.2.5.3. Product Benchmarking
  - 8.2.5.4. Strategic Initiatives
- 8.2.6. Meril
  - 8.2.6.1. Company Overview
  - 8.2.6.2. Financial Performance
  - 8.2.6.3. Product Benchmarking
  - 8.2.6.4. Strategic Initiatives
- 8.2.7. Gem srl
  - 8.2.7.1. Company Overview
  - 8.2.7.2. Financial Performance
  - 8.2.7.3. Product Benchmarking
  - 8.2.7.4. Strategic Initiatives
- 8.2.8. Balt
  - 8.2.8.1. Company Overview
  - 8.2.8.2. Financial Performance
  - 8.2.8.3. Product Benchmarking
  - 8.2.8.4. Strategic Initiatives
- 8.2.9. Sirtex (BlackSwan Vascular, Inc.)
  - 8.2.9.1. Company Overview
  - 8.2.9.2. Financial Performance
  - 8.2.9.3. Product Benchmarking
  - 8.2.9.4. Strategic Initiative
- 8.2.10. INVAMED
  - 8.2.10.1. Company Overview
  - 8.2.10.2. Financial Performance
  - 8.2.10.3. Product Benchmarking
  - 8.2.10.4. Strategic Initiatives
- 8.2.11. Stryker
  - 8.2.11.1. Company Overview
  - 8.2.11.2. Financial Performance
  - 8.2.11.3. Product Benchmarking
  - 8.2.11.4. Strategic Initiatives
- 8.2.12. Penumbra
  - 8.2.12.1. Company Overview
  - 8.2.12.2. Financial Performance
  - 8.2.12.3. Product Benchmarking
  - 8.2.12.4. Strategic Initiatives
- 8.2.13. Merit Medical Systems
  - 8.2.13.1. Company Overview
  - 8.2.13.2. Financial Performance
  - 8.2.13.3. Product Benchmarking
  - 8.2.13.4. Strategic Initiatives
- 8.2.14. Abbott
  - 8.2.14.1. Company Overview
  - 8.2.14.2. Financial Performance
  - 8.2.14.3. Product Benchmarking
  - 8.2.14.4. Strategic Initiatives
- 8.2.15. Acandis GmbH
  - 8.2.15.1. Company Overview
  - 8.2.15.2. Financial Performance
  - 8.2.15.3. Product Benchmarking
  - 8.2.15.4. Strategic Initiatives
- 8.2.16. Cook Medical
  - 8.2.16.1. Company Overview
  - 8.2.16.2. Financial Performance
  - 8.2.16.3. Product Benchmarking
  - 8.2.16.4. Strategic Initiatives

한글목차

색전요법 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 색전요법 시장의 변수, 동향, 범위

제4장 색전요법 시장 : 제품별 추정·동향 분석

제5장 색전요법 시장 : 용도별 추정·동향 분석

제6장 색전요법 시장 : 최종 용도별 추정·동향 분석

제7장 색전요법 시장 : 지역별 추정·동향 분석